company background image
CIPLA logo

Cipla NSEI:CIPLA Stock Report

Last Price

₹1.46k

Market Cap

₹1.2t

7D

-5.7%

1Y

17.4%

Updated

18 Nov, 2024

Data

Company Financials +

Cipla Limited

NSEI:CIPLA Stock Report

Market Cap: ₹1.2t

CIPLA Stock Overview

Engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. More details

CIPLA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends5/6

Rewards

Price-To-Earnings ratio (26.4x) is below the Indian market (31.1x)

Earnings are forecast to grow 7.29% per year

Earnings grew by 29.6% over the past year

Pays a reliable dividend of 0.89%

Trading at good value compared to peers and industry

Risk Analysis

CIPLA passed our risk checks.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions

Key Takeaways Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth. Strategic expansion in Africa and ongoing R&D investments aim to strengthen margins and sustain long-term profit growth.
View narrative
₹1.63k
FV
9.9% undervalued intrinsic discount
8.59%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
8 days ago author updated this narrative

Cipla Limited Competitors

Torrent Pharmaceuticals

BSE:500420

₹1.1t

Dr. Reddy's Laboratories

BSE:500124

₹994.0b

Zydus Lifesciences

NSEI:ZYDUSLIFE

₹950.6b

Lupin

BSE:500257

₹928.3b

Price History & Performance

Summary of all time highs, changes and price drops for Cipla
Historical stock prices
Current Share Price₹1,464.00
52 Week High₹1,702.05
52 Week Low₹1,164.55
Beta0.34
11 Month Change-5.65%
3 Month Change-6.33%
1 Year Change17.39%
33 Year Change63.50%
5 Year Change202.79%
Change since IPO45,268.16%

Recent News & Updates

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 01
Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 01
Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Cipla Limited's (NSE:CIPLA) Share Price Could Signal Some Risk

Sep 29
Cipla Limited's (NSE:CIPLA) Share Price Could Signal Some Risk

Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00

Jun 06
Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

May 21
Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14
Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

May 03
With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Feb 14
Is Cipla (NSE:CIPLA) Using Too Much Debt?

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Jan 26
Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Jan 08
Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Nov 15
Is Cipla (NSE:CIPLA) Using Too Much Debt?

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Oct 05
Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Aug 04
Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Is Cipla (NSE:CIPLA) A Risky Investment?

Mar 24
Is Cipla (NSE:CIPLA) A Risky Investment?

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Mar 06
A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Dec 11
Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Aug 19
Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Jul 30
Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Jul 14
Cipla (NSE:CIPLA) Could Easily Take On More Debt

If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Jul 01
If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 30
Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Mar 23
Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Dec 18
Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Shareholder Returns

CIPLAIN PharmaceuticalsIN Market
7D-5.7%-3.0%-3.3%
1Y17.4%42.9%27.5%

Return vs Industry: CIPLA underperformed the Indian Pharmaceuticals industry which returned 42.9% over the past year.

Return vs Market: CIPLA underperformed the Indian Market which returned 27.5% over the past year.

Price Volatility

Is CIPLA's price volatile compared to industry and market?
CIPLA volatility
CIPLA Average Weekly Movement4.0%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.2%
10% least volatile stocks in IN Market4.0%

Stable Share Price: CIPLA has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: CIPLA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
193527,764Umang Vohrawww.cipla.com

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry.

Cipla Limited Fundamentals Summary

How do Cipla's earnings and revenue compare to its market cap?
CIPLA fundamental statistics
Market cap₹1.21t
Earnings (TTM)₹44.75b
Revenue (TTM)₹262.64b

26.4x

P/E Ratio

4.5x

P/S Ratio

Is CIPLA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CIPLA income statement (TTM)
Revenue₹262.64b
Cost of Revenue₹89.70b
Gross Profit₹172.94b
Other Expenses₹128.19b
Earnings₹44.75b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)55.41
Gross Margin65.85%
Net Profit Margin17.04%
Debt/Equity Ratio0.6%

How did CIPLA perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

25%

Payout Ratio